The effect of eicosapentaenoic acid (EPA) on biomarkers of tumour growth and vascularity in human colorectal cancer liver metastases: The EMT (EPA for colorectal cancer Metastasis Trial) study.

Trial Profile

The effect of eicosapentaenoic acid (EPA) on biomarkers of tumour growth and vascularity in human colorectal cancer liver metastases: The EMT (EPA for colorectal cancer Metastasis Trial) study.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Eicosapentaenoic acid (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Biomarker; Pharmacodynamics
  • Acronyms EMT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Oct 2012 Safety and biomarker results presented at the 20th United European Gastroenterology Week.
    • 31 May 2012 Planned end date changed from 31 Jul 2011 to 1 Aug 2011 as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top